Clinical Trials Monitor

Efficacy and safety of neoadjuvant sintilimab, oxaliplatin and capecitabine in patients with locally advanced, resectable gastric or gastroesophageal junction adenocarcinoma: early results of a phase 2 study
Haiping Jiang, Xiongfei Yu, Ning Li, Mei Kong, Zhimin Ma, Donghui Zhou, Weibin Wang, Haohao Wang, Haiyong Wang, Kuifeng He, Zhongqi Li, Yimin Lu, Jing Zhang, Kui Zhao, Yafei Zhang, Nong Xu, Ziran Li, Ying Liu, Yan Wang, Yisen Wang, Lisong Teng

Journal for ImmunoTherapy of Cancer Mar 2022, 10 (3) e003635; DOI: 10.1136/jitc-2021-003635
‘You give me fever!’: are health services ready for immune cell engager therapy in advanced solid malignancies?
Claire Pettinger, Claire Livings, Rafael Grochot, Andrew Furness, Juanita Lopez

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e006073; DOI: 10.1136/jitc-2022-006073
GB1275, a first-in-class CD11b modulator: rationale for immunotherapeutic combinations in solid tumors
David G DeNardo, Anna Galkin, Jakob Dupont, Lei Zhou, Johanna Bendell

Journal for ImmunoTherapy of Cancer Aug 2021, 9 (8) e003005; DOI: 10.1136/jitc-2021-003005
Evaluating the efficacy of a priming dose of cyclophosphamide prior to pembrolizumab to treat metastatic triple negative breast cancer
Carey K Anders, Mark G Woodcock, Amanda E D Van Swearingen, Dominic T Moore, Maria J Sambade, Sonia Laurie, Alexander Robeson, Oleg Kolupaev, Luz A Cuaboy, Amy L Garrett, Karen McKinnon, Kristen Cowens, Dante Bortone, Benjamin C Calhoun, Alec D Wilkinson, Lisa Carey, Trevor Jolly, Hyman Muss, Katherine Reeder-Hayes, Rebecca Kaltman, Rachel Jankowitz, Vinay Gudena, Oludamilola Olajide, Charles Perou, E Claire Dees, Benjamin G Vincent, Jonathan S Serody

Journal for ImmunoTherapy of Cancer Feb 2022, 10 (2) e003427; DOI: 10.1136/jitc-2021-003427
Targeting adenosine for cancer immunotherapy
Robert D. Leone, Leisha A. Emens

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 57; DOI: 10.1186/s40425-018-0360-8
Design considerations for early-phase clinical trials of immune-oncology agents
Nolan A. Wages, Cody Chiuzan, Katherine S. Panageas

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 81; DOI: 10.1186/s40425-018-0389-8
Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer
Jason M. Redman, Seth M. Steinberg, James L. Gulley

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 91; DOI: 10.1186/s40425-018-0409-8
Immune cell concentrations among the primary tumor microenvironment in colorectal cancer patients predicted by clinicopathologic characteristics and blood indexes
Guifang Guo, Yixing Wang, Yixin Zhou, Qi Quan, Yijun Zhang, Haohua Wang, Bei Zhang, Liangping Xia

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 179; DOI: 10.1186/s40425-019-0656-3
The motility regulator flhDC drives intracellular accumulation and tumor colonization of Salmonella
Vishnu Raman, Nele Van Dessel, Owen M. O’Connor, Neil S. Forbes

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 44; DOI: 10.1186/s40425-018-0490-z
Immunotherapy for Merkel cell carcinoma: a turning point in patient care
Isaac S. Chan, Shailender Bhatia, Howard L. Kaufman, Evan J. Lipson

Journal for ImmunoTherapy of Cancer Dec 2018, 6 (1) 23; DOI: 10.1186/s40425-018-0335-9

Main menu

Clinical Trials Monitor

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Clinical Trials Monitor

Pages